Use of the afirma® gene expression classifier for preoperative identification of benign thyroid nodules with indeterminate fine needle aspiration cytopathology

Syed Z Ali, Stephanie A Fish, Richard Lanman, Gregory W Randolph, Julie Ann Sosa, Syed Z Ali, Stephanie A Fish, Richard Lanman, Gregory W Randolph, Julie Ann Sosa

Abstract

Ruling out malignancy in thyroid nodules historically depended on thyroid resection and histopathological evaluation until fine needle aspiration (FNA) biopsy was introduced into the United States in the 1970's. Thyroid FNA biopsy identified a majority of thyroid nodules as benign, obviating the need for surgery in over half of the patients. However, 15%-30% of thyroid FNAs have indeterminate cytology that still requires operation, even though most of these operated nodules prove to be benign post-operatively. In order to predict which cytologically indeterminate thyroid nodules are benign and to potentially avoid surgery on these nodules, a recently described commercially available Gene Expression Classifier (GEC) test (Afirma®, Veracyte, Inc., South San Francisco, CA) has been developed that can be run on the FNA sample. This paper reviews the published literature and technology assessments/guidelines by independent parties and professional groups regarding the clinical utility as well as the analytic and clinical validity of the Afirma GEC.

References

    1. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, Vitti P. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest. 2010;33(5 Suppl):51-6. PubMed PMID:20543551.
    1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov;19(11):1167-214. PubMed PMID:19860577.
    1. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov;8(11):1228-74. PubMed PMID:21081783.
    1. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009 Nov;19(11):1159-65. PubMed PMID:19888858.
    1. Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E, Fellegara G, Rosai J, Livolsi V, Lanman RB. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011 Mar;21(3):243-51. PubMed PMID:21190442.
    1. Bryson PC, Shores CG, Hart C, Thorne L, Patel MR, Richey L, Farag A, Zanation AM. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):581-6. PubMed PMID:18559722.
    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. PubMed PMID:21685461.
    1. NCCN Clinical Practice Guidelines Thyroid Carcinoma Version 1.2013. December 21, 2012.
    1. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2011 Nov;96(11):E1719-26. PubMed PMID:21865367.
    1. Jameson JL. Minimizing unnecessary surgery for thyroid nodules. N Engl J Med. 2012 Aug 23;367(8):765-7. PubMed PMID:22731671.
    1. Kim MI, Alexander EK. Diagnostic use of molecular markers in the evaluation of thyroid nodules. Endocr Pract. 2012 Sep-Oct;18(5):796-802. PubMed PMID:22982803.
    1. Melillo RM, Santoro M. Molecular biomarkers in thyroid FNA samples. J Clin Endocrinol Metab. 2012 Dec;97(12):4370-3. PubMed PMID:23223485.
    1. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011 Jul;96(7):2016-26. PubMed PMID:21593119.
    1. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, Reynolds J, Tom E, Pagan M, Rigl CT, Friedman L, Wang CC, Lanman RB, Zeiger M, Kebebew E, Rosai J, Fellegara G, LiVolsi VA, Kennedy GC. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010 Dec;95(12):5296-304. PubMed PMID:20826580.
    1. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 Aug 23;367(8):705-15. PubMed PMID:22731672.
    1. Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012 Oct;22(10):996-1001. PubMed PMID:22873825.
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. PubMed PMID:19474385.
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. PubMed PMID:23335087.
    1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006 May 10;295(18):2164-7. PubMed PMID:16684987.
    1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993 Feb 25;328(8):553-9. PubMed PMID:8426623.
    1. Randolph GW (ed). Surgery of the Thyroid and Parathyroid Glands. 2nd edition Philadelphia, PA: Elsevier Saunders, 2012.
    1. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998 Sep;228(3):320-30. PubMed PMID:9742915.
    1. Bergenfelz A, Jansson S, Kristoffersson A, Mårtensson H, Reihnér E, Wallin G, Lausen I. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg. 2008 Sep;393(5):667-73. PubMed PMID:18633639.
    1. Saunders BD, Wainess RM, Dimick JB, Doherty GM, Upchurch GR, Gauger PG. Who performs endocrine operations in the United States? Surgery. 2003 Dec;134(6):924-31; discussion 931. PubMed PMID:14668724.
    1. Palmetto GBA. Local Coverage Article for MolDx: AFIRMA™ Assay by Veracyte Update (Article ID Number A51697). January 1, 2012.
    1. Statley D. CLIA Examiner I Report. September 29, 2010.
    1. Klees RF. Assay Validation Review. July 27, 2012.
    1. NCCN Biomarkers Compendium. Accessed December 21, 2012.
    1. Walsh PS, Wilde JI, Tom EY, Reynolds JD, Chen DC, Chudova DI, Pagan M, Pankratz DG, Wong M, Veitch J, Friedman L, Monroe R, Steward DL, Lupo MA, Lanman RB, Kennedy GC. Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab. 2012 Dec;97(12):E2297-306. PubMed PMID:23087323.
    1. Lewis CM, Chang KP, Pitman M, Faquin WC, Randolph GW. Thyroid fine-needle aspiration biopsy: variability in reporting. Thyroid. 2009 Jul;19(7):717-23. PubMed PMID:19485775.
    1. Agresti A, Coull BA. Approximate Is Better than “Exact” for Interval Estimation of Binomial Proportions. Amer Statistician 1998 May;52(2):119-126.
    1. Monroe R, Zalles C, Traweek T, O’Reilly K, Romanowsky J, Brunt K, Kennedy GC, Lanman RB 2011 Clinical practice impact of a novel mRNA–based gene expression classifier in thyroid nodules with indeterminate fine needle aspiration cytopathology. Thyroid 21:A-101 (Poster 244; abstract).
    1. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009 Jan;11(1):3-14. PubMed PMID:18813139.
    1. National Office of Public Health Genomics, CDC. ACCE model system for collecting, analyzing and disseminating information on genetic tests. Accessed November 4, 2012.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する